The U.S. health regulator added the FDA’s strictest warning to the labels of drugs from Pfizer, Eli Lilly and AbbVie belonging to a class of anti-inflammatory treatments called JAK inhibitors, citing risk of serious health issues and death in patients 50 and over, the drugmakers said on December 3.
A judge in Hawaii ordered Bristol-Myers Squibb Co. and Sanofi SA to pay more than $834 million to the state for failing to warn non-white patients properly of health risks from the blood thinner Plavix.
A new study finds that one-third of adults in the United States are potentially at risk of depression due to their medications.
Massachusetts’ top court opened the door for consumers to sue Merck and other brand-name drug makers over injuries blamed on generic forms of their treatments made by other companies.
A federal appeals court revived claims by plaintiffs accusing Merck & Co. of failing to adequately warn about risks of thigh bone fractures associated with Fosamax.
Regeneron CEO Len Schleifer ripped into Amgen for its insistence on blocking sales of a rival cholesterol drug during the appeals process in a patent infringement case.
A restaurant industry trade group is suing New York City’s Board of Health to stop it from enforcing a new rule requiring many chain restaurants to post warnings on menu […]
U.S. health regulators on Tuesday approved Amgen Inc’s novel cancer immunotherapy for injection into melanoma lesions and lymph nodes of patients with the deadliest form of skin cancer that returns […]
The U.S. Food and Drug Administration approved Relypsa Inc’s drug to treat potentially fatal levels of potassium in patients with chronic kidney disease or heart problems. The drug, Veltassa, is […]
The U.S. food and Drug Administration said it was strengthening an existing warning label that non-aspirin, non-steroidal anti-inflammatory drugs (NSAIDs) increase the chance of a heart attack or stroke. NSAIDs […]